Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Oncolytics Biotech ( (TSE:ONC) ) has issued an update.
Oncolytics Biotech has made significant progress in its pancreatic and anal cancer trials, strengthening its pipeline for 2025. The company received regulatory clearance from Germany’s Paul-Ehrlich-Institute to continue enrolling patients in its pancreatic cancer study, indicating positive safety reviews. Additionally, recent clinical data presented at the 2025 ASCO Gastrointestinal Cancers Symposium demonstrated pelareorep’s potential efficacy and safety in treating pancreatic and anal cancers. These developments de-risk pelareorep’s progression and could lead to larger clinical trials, potentially enhancing treatment options and creating shareholder value.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage company that specializes in immunotherapy for oncology. The company focuses on developing pelareorep, an immunotherapy treatment, with a market focus on hard-to-treat cancers such as pancreatic, anal, and breast cancer.
YTD Price Performance: -17.53%
Average Trading Volume: 1,238,109
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $60.25M
For detailed information about ONC stock, go to TipRanks’ Stock Analysis page.
